Cure8 research brief
AI models are being developed to support IBD care (activity scoring, risk prediction), but most studies are retrospective and don’t yet demonstrate that AI outputs reliably change clinical decisions or improve outcomes. Patients and clinicians should know that more prospective validation is needed.
Clinicians working in gastroenterology and IBD, clinical researchers developing or validating AI tools, implementation scientists, and health system leaders planning AI deployment.
This structured narrative review surveys AI use in endoscopy, IBD, hepatology and pancreaticobiliary disease, focusing on three translational priorities: explainability (can clinicians and patients understand model outputs?), generalisability (do models work across sites, devices and populations?), and clinical actionability (do outputs change care or outcomes?).
The authors find the strongest evidence in endoscopic applications (for example, polyp detection), while IBD-related AI work remains mainly retrospective with few prospective or health-economic studies. Common technical approaches like heatmaps are used for explainability but are rarely tested for how they affect clinician trust or patient communication.
Practical implications include the need for clearly defined clinical use cases, multicentre external validation, human-centred evaluation, prospective trials assessing benefits and harms, and continuous surveillance after deployment.
The review treats AI as a sociotechnical intervention—not just a model but also its interface, users, workflows and communication processes.
This entry is based on the article abstract (structured-content depth: abstract). The paper is a narrative review summarising published evidence and emphasizing implementation gaps; it does not present a single new clinical trial result. Prospective, multicentre and health-economic evaluations remain uncommon according to the authors.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Non-specialist physicians often manage IBD where specialists are scarce. If reliable, AI tools could improve non-specialists' clinical reasoning and decision-making for IBD care.
Genetic ancestry can influence IBD risk and disease course, and most prior studies focused on European populations.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
